Marché des thérapies et des diagnostics de l’insuffisance pancréatique exocrine (IPE) au Moyen-Orient et en Afrique – Tendances et prévisions de l’industrie jusqu’en 2030

Analyse et perspectives du marché des thérapies et des diagnostics de l'insuffisance pancréatique exocrine (IPE) au Moyen-Orient et en Afrique

La prise de conscience croissante des technologies de diagnostic avancées au Moyen-Orient et en Afrique a accru la demande sur le marché. L'augmentation des dépenses de santé pour de meilleurs services de santé contribue également à la croissance du marché. Les principaux acteurs du marché se concentrent sur divers lancements et approbations de services au cours de cette période cruciale. En outre, l'augmentation des progrès des processus et des techniques contribue également à la demande croissante de produits thérapeutiques et de diagnostics pour l'insuffisance pancréatique exocrine (IPE).

Le marché des thérapies et des diagnostics de l'insuffisance pancréatique exocrine (IPE) au Moyen-Orient et en Afrique devrait croître au cours de l'année de prévision en raison de l'augmentation du nombre d'acteurs sur le marché et de la disponibilité de services avancés. Parallèlement à cela, les fabricants sont engagés dans l'activité de développement pour lancer de nouveaux services sur le marché. Le développement croissant des techniques de soins de santé avancées stimule encore la croissance du marché. Cependant, des difficultés telles que les réglementations strictes qui entravent le secteur thérapeutique et diagnostique de l'insuffisance pancréatique exocrine (IPE), les effets secondaires et les obstacles religieux associés à la thérapie de remplacement des enzymes pancréatiques (PERT) pourraient entraver la croissance du marché des thérapies et des diagnostics de l'insuffisance pancréatique exocrine (IPE) au Moyen-Orient et en Afrique au cours de la période de prévision.

L'augmentation des dépenses de santé consacrées au développement et à l'avancement des soins devrait ouvrir des opportunités au marché. Cependant, le coût élevé associé au diagnostic et au traitement de l'EPI pourrait remettre en cause la croissance du marché.

Data Bridge Market Research analyse que le marché des thérapies et des diagnostics de l'insuffisance pancréatique exocrine (EPI) au Moyen-Orient et en Afrique devrait atteindre la valeur de 664,24 millions USD d'ici 2030, à un TCAC de 5,8 % au cours de la période de prévision.

Market Definition

Exocrine pancreatic insufficiency (EPI) is a medical condition where the pancreas fails to produce enough digestive enzymes to digest fats, proteins, and carbohydrates in the intestine. EPI can be caused by various conditions, such as chronic pancreatitis, cystic fibrosis, and pancreatic cancer. Therapeutics for EPI involve using pancreatic enzyme replacement therapy (PERT), which provides the necessary digestive enzymes that the pancreas is not producing. PERT is usually taken with meals and snacks to help break down food and absorb nutrients properly; several PERT products are available, such as pancrelipase, pancreatin, and lipase.

Diagnostics for EPI may involve blood tests to measure the levels of digestive enzymes in the blood, fecal elastase test to check the level of pancreatic elastase in the stool, and imaging tests, such as CT scans, MRI, or endoscopic ultrasound to visualize the pancreas and detect any abnormalities. Additionally, breath tests can measure the levels of hydrogen and methane in the breath, indicating EPI. 

Middle East and Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Dynamics

This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:     

Drivers

• Increasing prevalence of exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis and cystic fibrosis

Exocrine pancreatic insufficiency (EPI) is a condition caused when the pancreas fails to make sufficient amounts of digestive enzymes to help digestion and absorption of nutrients. Chronic pancreatitis is the main cause of EPI in adults. Pancreatitis causes inflammation and swelling of the pancreas. Over time, it can damage the pancreatic cells that make digestive enzymes. Similarly, cystic fibrosis is one of the main causes of EPI in children. It is inherited from parents and causes thick mucus to build up in the lungs, creating difficulty breathing. Mucus also accumulates in the pancreas and prevents digestive enzymes from reaching the small intestine. People with EPI can’t absorb enough fats, proteins, and carbohydrates from foods which is called malabsorption.

Therefore, the increasing prevalence of EPI due to chronic pancreatitis and cystic fibrosis is driving the growth of the market in the forecast period.

•   Rising technological advancements in the diagnosis and treatment of EPI

There is a lack of consensus regarding the best diagnostic approach, and experts have noted the non-reliability and non-specificity of available diagnostic tests. Available diagnostic tests for EPI include fecal fat quantification, the fecal elastase-1 test, and the C-mixed triglyceride breath test. Developing a machine learning model that identifies patients in a commercial medical claims database who likely have EPI but are undiagnosed is one of the recent objectives to advance the diagnosis and treatment framework of EPI.

Therefore, the rising technological advancements in the diagnosis and treatment of EPI is driving the market's growth in the forecast period.

Restraint

• Stringent regulations to hamper the exocrine pancreatic insufficiency (EPI) therapeutic and diagnostic sector

The use of therapies and medications for EPI disorders across the globe is rapidly increasing, with the growth of the aged population and several chronic diseases which are preventable by early diagnosis. At the same time, the players of the EPI disorders products manufacturers in the market must follow certain regulations to get approval from the upper authorities for launching the product in the market. These stringent guidelines need to be followed and this is one of the most difficult tasks of all the steps. The U.S. Food and Drug Administration (FDA) regulates the U.S. and the European Union (EU) regulates Europe. However, the rapid development of privacy policies and regulations is being made in the Asia-Pacific and EMEA, including India, Russia, China, South Korea, Singapore, Hong Kong, and Australia. Some drug regulatory agencies, including the U.S. Food and Drug Administration (FDA), have instructed that manufacturers obtain regulatory approvals before marketing their products because of possible adverse effects and inadequate effectiveness. These stringent FDA regulations have made approval of pancrelipase products difficult.

Hence, from the above instances, concluded that stringent regulations may restrain the growth of the exocrine therapeutic insufficiency therapeutics and diagnostics market in the forecast period.

Opportunity

• Increasing prevalence of pancreatic disorders and associated condition

EPI is a prominent side effect of pancreatic diseases like cancer, cystic fibrosis, and chronic pancreatitis. These ailments can harm the pancreas, impairing its capacity to generate digestive enzymes and result in EPI. The rising prevalence of pancreatic diseases and related ailments worldwide is driving the demand for EPI therapies and diagnostics. These conditions can cause damage to the pancreas, leading to a reduced ability to produce digestive enzymes, which can result in EPI. Cystic fibrosis's damage to the pancreas makes it another disorder that can result in EPI. The genetic disease known as cystic fibrosis impacts the reproductive, digestive, and respiratory systems. Cystic fibrosis is more common in Caucasians, particularly those with a Northern European ancestry, than worldwide. As the incidence of these conditions continues to increase, the demand for EPI therapeutics and diagnostics is also expected to grow. This presents a significant opportunity for pharmaceutical companies and manufacturers to develop new and effective treatments and diagnostic tests for EPI.

Thus, the increasing prevalence of pancreatic disorders and associated conditions is expected to act as an opportunity for market growth.

Challenge

• High cost associated with EPI diagnosis and treatment

The complexity of the illness and the requirement for specialized tests make the diagnosis of EPI expensive. Faecal elastase testing, secretin-stimulated pancreatic function testing, and imaging tests like magnetic resonance imaging (MRI) and endoscopic ultrasonography (EUS) are the most frequently used diagnostic procedures for EPI. These tests can be pricey, and not all medical professionals can access the tools and training needed to carry them out.  The high expense of identifying EPI can also delay a diagnosis, which can exacerbate symptoms and raise healthcare costs over time. Untreated EPI can cause continuing digestive problems, nutrient malabsorption, and weight loss in patients, all of which can increase medical expenses and difficulties.

Thus, the high cost associated with EPI diagnosis and treatment is expected to act as a challenge in the market growth.

Recent Developments

• In August 2021, AzurRx announced that it had engaged in the development of yeast-derived lipase, MS1819, which has been engineered to have superior enzymatic activity as compared to current treatments.
• In February 2023, Codexis, Inc. and Nestlé Health Science announced the interim findings from a Phase 1 trial examining the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of CDX-7108. A lipase variation called CDX-7108 was created expressly to get around the drawbacks of the current pancreatic enzyme replacement treatment (PERT). This has aided the business in marketing the product.

Middle East and Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Scope

The Middle East and Africa exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is categorized into five notable segments such as diagnosis, treatment, drug type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.   

Diagnosis

• Imaging Tests
• Pancreatic Function Test

On the basis of diagnosis, the Middle East and Africa exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is segmented into imaging test and pancreatic function test.

Treatment

• Nutritional Management
• Pancreatic Enzyme Replacement Therapy (PERT)

On the basis of treatment, the Middle East and Africa exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is segmented into nutritional management and pancreatic enzyme replacement therapy (PERT).

Drug Type

• Generic
• Branded

On the basis of drug type, the Middle East and Africa exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is segmented into generic and branded.

End User

• Hospitals
• Specialty Clinics
• Homecare
• Diagnostic Centre
• Research and Academic Institutes
• Others

On the basis of end user, the Middle East and Africa exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is segmented into Hospitals, Specialty Clinics, Homecare, Diagnostic Centers, Research and Academic Institute, and others.

Distribution Channel

• Direct Tender
• Retail Pharmacy 
• Third-Party Distributor
• Others

On the basis of distribution channel, the Middle East and Africa exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is segmented into direct tender, retail pharmacy, third party distributor, and others.

Middle East and Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Regional Analysis/Insights

The Middle East and Africa exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is categorized into five notable segments such as diagnosis, treatment, drug type, end user, and distribution channel.    

The countries covered in this market report are South Africa, Saudi Arabia, Bahrain, Kuwait, Qatar, Oman, U.A.E., Egypt, Israel, and Rest of Middle East and Africa.

South Africa is dominating due to the presence of key market players in the largest consumer market with high GDP.

La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie des pays, les actes réglementaires et les tarifs d'importation et d'exportation sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques du Moyen-Orient et d'Afrique et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, ainsi que l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.

Paysage concurrentiel et analyse des parts de marché des produits thérapeutiques et diagnostiques pour l'insuffisance pancréatique exocrine (IPE) au Moyen-Orient et en Afrique

Le paysage concurrentiel du marché des thérapies et des diagnostics de l'insuffisance pancréatique exocrine (IPE) au Moyen-Orient et en Afrique fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les approbations de produits, la largeur et la portée du produit, la domination des applications et la courbe de survie du type de produit. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise vers le marché des systèmes d'appel infirmier au Moyen-Orient et en Afrique.

Certains des principaux acteurs opérant sur le marché des thérapies et des diagnostics de l'insuffisance pancréatique exocrine (IPE) au Moyen-Orient et en Afrique sont EagleBio, AbbVie. Nordmark Arzneimittel GmbH & Co., Digestive Care, Inc., Cilian AG, Alcresta Therapeutics, Inc., ChiRhoClin, Abbott, Bioserv Diagnostics, Laboratory Corporation of America, le groupe de sociétés Organon Metagenics LLC, Janssen, Nestlé., VIVUS LLC. et ScheBo Biotech AG, entre autres.

SKU-70030